Background: Low-normal thyroid function within the euthyroid range has been
function are still incompletely understood. Low-normal thyroid function is associated with a modest increase in plasma total cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides. [4] [5] [6] [7] Low-normal thyroid function may also attenuate high-density lipoproteins (HDL) function, such as its ability to protect against oxidative stress.
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Accumulating evidence supports the hypothesis that systemic oxidative stress, as at least in part reflected by enhanced oxidative modification of LDL, may contribute to the development of atherosclerosis. [9] [10] [11] In this context, it is relevant that LDL oxidation in vitro is exaggerated in both hypothyroidism and hyperthyroidism. 12, 13 Moreover, increased circulating oxidized LDL levels have been demonstrated in euthyroid subjects with higher TSH levels. 14 Paraoxonase-1 (PON-1) is a HDL-associated hydrolytic enzyme with important anti-oxidative properties. 15 PON-1 hydrolyzes lipid peroxides, thereby preventing their accumulation in LDL particles. 15, 16 Studies in rodent models and humans have suggested that the anti-atherogenic effects of the HDL fraction are to a considerable extent attributable to PON-1 activity. 16 Paraoxonase-1 (PON-1) activity has been shown to be impaired in patients with metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM) and hypercholesterolaemia. 15, [17] [18] [19] Furthermore, lower serum PON-1 activity may predict increased risk of coronary events, 20, 21 although the association of PON-1 activity with increased CVD risk was not independent of HDL cholesterol. 22 The effect of thyroid dysfunction on serum PON-1 activity has only been determined in a limited number of studies. [23] [24] [25] [26] [27] Remarkably, PON-1 activity was found to be impaired in both hypothyroidism and hyperthyroidism. 23 In addition, PON-1 activity was decreased in (subclinical) hypothyroidism in some, 24, 25 but not in other studies. [26] [27] [28] No data are currently available concerning the association of serum PON-1 activity in the context of variations in thyroid hormone levels within the euthyroid range. Against this background, we performed this study to evaluate the relationships of serum PON-1 activity with thyroid function in euthyroid subjects. In view of decreased PON-1 activity in MetS 15 and potential alterations in thyroid hormones in MetS, 4 we also determined the extent to which such a relationship is modified by the presence of MetS and its individual components.
| SUBJECTS AND METHODS

| Subjects
Reporting of the study conforms to STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) statement along with references to STROBE statement and the broader EQUATOR guidelines. 29 The study population consisted of a random subset of participants of the PREVEND (Prevention of Renal and Vascular End Stage Disease) cohort, aged 28-75 years, living in the city of Groningen, the Netherlands. Participants were predominantly of Caucasian origin (94.2%). The protocol of this study has been described in detail elsewhere. 30, 31 The local medical ethical committee approved the study; all participants gave written informed consent. For the current analysis, we excluded subjects not being euthyroid, subjects using thyroid hormones, antithyroid drugs, amiodarone and lithium carbonate. Euthyroidism was defined as TSH, free T 4 and free T 3 levels each within the respective reference range as provided by the manufacturer (see Laboratory Analyses). We additionally excluded subjects with positive antithyroid peroxidase autoantibodies (cut-off value: see Laboratory Analyses). Information on self-reported medication use was combined with information from a pharmacy-dispensing registry, which has complete information on drug of >95% of subjects in the PREVEND study. Applying these selection criteria, 2206 subjects were eligible for the current analyses.
The presence of a self-reported history of myocardial infarction, percutaneous coronary intervention, coronary artery bypass surgery, stroke or the diagnosis of narrowing of one or both carotid arteries was defined as CVD. Type 2 diabetes mellitus (T2DM) was defined as a fasting serum glucose concentration >7.0 mmol/L, a nonfasting plasma glucose concentration >11.1 mmol/L, a self-report of a physician diagnosis or the use of glucose-lowering drugs. To categorize subjects with the metabolic syndrome (MetS), 3 or more of the following criteria were required: waist circumference > 102 cm for men and >88 cm for women, hypertension (blood pressure ≥ 130⁄85 mm Hg or use of antihypertensive drugs), fasting plasma triglycerides ≥ 1.70 mmol/L, fasting glucose ≥ 5.6 mmol/L (or use of glucose-lowering drugs) and HDL cholesterol < 1.03 mmol/L for men and <1.29 mmol/L for women applying NCEP ATPIII criteria. 32 Patient characteristics including age, sex, alcohol use, smoking status, body mass index (BMI), waist circumference, systolic and diastolic blood pressure were obtained. The participants were instructed to let venous blood samples being drawn after an overnight fast for measurement of, glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, TSH, free T 4 and free T 3 and PON-1 activity. Urinary albumin excretion (UAE) was documented as the mean of two 24-hour urine collections. Body mass index (BMI) was defined as weight (kg) by height (m) squared. Waist circumference (WC) was measured on bare skin between the 10th rib and iliac crest. Alcohol consumption was recorded with one drink being assumed to contain 10 g of alcohol. Smoking was categorized into current, former and never. Estimated glomerular filtration rate (eGFR) was calculated with the use of the combined creatinine-cystatin C-based Chronic Kidney Disease Epidemiology Collaboration equation. 33 
| Laboratory analyses
Heparinized plasma samples were stored at À80°C until analyses. Sera were stored at À80°C until analyses. Serum TSH (Architect; Abbott Laboratories, Abbott Park, IL, USA; reference range 0. .94 mU/L), free T 4 (AxSYM; Abbott Laboratories; reference range 9.14-23.81 pmol/L) and free T 3 (AxSYM; Abbott Laboratories; reference range; 2.23-5.35 pmol/L) were measured by microparticle enzyme immunoassays. Antithyroid peroxidase autoantibodies were determined using commercially available automated enzyme-linked immunoassays (Abbott Laboratories; kit number 5F57). Antithyroid peroxidase autoantibodies were considered positive using a cut-off value as indicated by the supplier (≥12 kU/L).
Serum PON-1 enzymatic activity was measured as its arylesterase activity, that is, as the rate of hydrolysis of phenyl acetate into phenol, as described. 34 The interassay CV was 8%. arylesterase activity, measured with this assay, is positively correlated with PON-1 enzymatic activity towards paraoxon as well as with PON-1 mass. 35 Total serum cholesterol and plasma glucose were measured using Kodak Ektachem dry chemistry (Eastman Kodak, Rochester, NY, USA). Serum triglycerides were measured enzymatically. High-density lipoproteins (HDL) cholesterol was measured with a homogeneous method (direct HDL, AEROSET system; Abbott Laboratories; no. 7D67). Non-HDL cholesterol was calculated as the difference between total cholesterol and HDL cholesterol. Serum apoA-I was determined by nephelometry applying commercially available reagents for Dade Behring nephelometer systems (BN II; Dade Behring, Marburg, Germany; apoA-I test kit, code no. OUED).
Serum creatinine was measured by an enzymatic method on a Roche Modular analyser (Roche Diagnostics, Mannheim, Germany). Serum cystatin C was measured by Gentian cystatin C immunoassay (Gentian AS, Moss, Norway) on a Modular analyser (Roche Diagnostics). Urinary albumin concentration was measured by nephelometry with a threshold of 2.3 mg/L (Dade Behring Diagnostic, Marburg, Germany).
| Statistical analyses
Data analysis was performed using IBM SPSS software (version 23.0, SPSS Inc. Chicago, IL, USA). Normally distributed data are given as mean AE SD, and nonparametrically distributed data are presented as median (interquartile range). Categorical variables are given as percentages. Differences in PON-1 activity between men and women were determined by Mann-Whitney U test. Clinical and laboratory characteristics of the study population are presented according to sex-stratified tertiles of PON-1 activity. Differences in proportions of dichotomous variables across tertiles of PON-1 activity were determined by multinomial chi-square tests. Multivariable linear regression analyses, adjusted for age and sex, were used to test for linear trends between tertiles of PON-1 activity. Age-and sex-adjusted multivariable linear regression analyses were also used to determine the extent to which PON-1 activity (as continuous variable) was related to thyroid function parameters (TSH, free T 4 , free T 3 ) taking clinical and laboratory covariates into account. Paraoxonase-1 (PON-1) activity, TSH, triglycerides and UAE were natural logarithm (log e ) transformed to achieve approximately normal distributions. Interaction terms were calculated as the product term of TSH or free T 4 with sex or the presence of MetS or its component of interest. To account for outliers, the individual TSH or free T 4 values were centred to the mean by subtracting the group mean value from individual values. 36, 37 Interaction terms were considered statistically significant at P-values <.10, as recommended by Selvin.
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Otherwise, two-sided P-values <.05 were considered significant. (Table 1) . One hundred two participants (4.6%) reported a previous cardiovascular event, 65 subjects (2.9%) had T2DM and 418 (19%) subjects fulfilled the criteria for MetS. A history of CVD (P = .002) and the presence of MetS (P = .013) were more prevalent in subjects categorized in the lowest tertile of PON-1 activity, but diabetes status did not significantly vary according to the PON-1 categories (P = .096) ( Table 1) . Oral glucose-lowering drugs were used by 36 subjects, lipid-modifying drugs (mainly statins) by 113 participants and antihypertensives by 274 subjects. Oral contraceptives were used by 283 women. The use of oral glucose-lowering drugs (P < .002, antihypertensives (P < .001) was more prevalent in the subjects belonging to the lowest tertile of PON-1 activity, whereas the use of oral contraceptives was more prevalent in the women belonging to the highest tertile of PON-1 activity (P < .001) (data not VAN TIENHOVEN-WIND ET AL.
| RESULTS
shown). The use of lipid-lowering drugs did not vary across tertiles of PON-I activity (P = .17). Accordingly, serum PON-1 activity was lower in subjects using oral glucose-lowering drugs (45. .5] U/L, P = .10). Serum PON-1 activity was inversely related to age. In age-and sex-adjusted analysis, PON-1 activity was positively related to systolic and diastolic blood pressure (Table 1) . Paraoxonase-1 (PON-1) activity was unrelated to BMI, waist circumference, glucose, eGFR and UAE, and did not vary significantly according to smoking status and alcohol consumption. Additionally, PON-1 activity was positively related to total cholesterol, non-HDL cholesterol, triglycerides, as well as to HDL cholesterol and apoA-I (Table 1 ). Of note, in age-and sexadjusted analysis, PON-1 activity was positively related to TSH and inversely to free T 4 , but not to free T 3 ( Table 1 ). Figure 1 shows TSH, free T 4 and free T 3 levels according to sex-stratified tertiles of PON-1 activity. There were no interactions of sex with TSH, free T 4 or free T 3 on PON-1 activity (P = .52 to P = .64; data not shown).
We then tested whether the relationships of PON-1 activity (as continuous variable) with TSH and free T 4 remained present after adjustment for relevant clinical and laboratory covariates ( Table 2 ). In age-and sex-adjusted multivariable linear regression analysis including free T 4 and TSH together, PON-1 activity was positively associated with TSH and inversely with free T 4 (Table 2, model 1). In analysis with free T 4 , free T 3 and TSH together, there was no significant independent association of PON-1 activity with free T 3 (b = À0.029, P = .18; data not shown). The inverse relationship of PON-1 activity with free T 4 remained present after additional adjustment for non-HDL cholesterol, HDL cholesterol and triglycerides, although the positive relationship of PON-1 activity with TSH lost significance ( Table 2 , model 2). Likewise, PON-1 activity was inversely related to free T 4 in an alternative model which included apoA-I instead of HDL cholesterol (b = À0.055, P = .01; data not shown). An inverse relationship of PON-1 activity with free T 4 was also found after additional adjustment for systolic and diastolic blood pressure, UAE, eGFR, alcohol consumption, smoking, a previous history of cardiovascular disease and diabetes status (Table 2 , model 3), and finally after further adjustment for oral glucose-lowering drugs, lipid-lowering medication, antihypertensives and oral contraceptives (Table 2, model 4). The inverse relationship of PON-1 activity with free T 4 was not different in subjects with vs without MetS (P = .94), nor modified by the presence of its individual components (low HDL cholesterol: P = .58; elevated triglycerides: P = .96; enlarged waist circumference: P = .57; elevated blood pressure: P = .31; elevated glucose:
Secondary analyses were performed after exclusion of subjects with a previous history of CVD and T2DM (n = 2051, Table 3 , model 1), as well as after exclusion of subjects using oral glucose-lowering drugs, lipid-lowering drugs, antihypertensives and oral contraceptives (n = 1596, Table 3 , model 2). In both analyses, PON-I activity remained inversely associated with free T 4 (b = À0.047 to À0.049, P = .035-.049) taking account of age, sex, non-HDL cholesterol, HDL cholesterol, triglycerides, systolic and diastolic blood pressure, alcohol consumption and smoking status (data not shown). In these analyses, PON-1 activity was also positively related to HDL cholesterol (b = 0.236-0.217, P < .001).
| DISCUSSION
In this large population-based study among strictly euthyroid subjects, we have shown to our knowledge for the first time that serum PON-1 activity is positively related to TSH and inversely to free T 4 in age-and sex-adjusted analysis. In multivariable logistic regression analysis in which we included TSH, free T 4 and free T 3 together and adjusted for lipoproteins and other potentially important covariates, the inverse association of PON-1 activity with free T 4 remained present. The inverse relationship of PON-1 activity with free T 4 was not different between subjects with and without MetS nor modified by the presence of its individual components. Our current results are, therefore, in agreement with the hypothesis that variations in thyroid function within the euthyroid range may affect serum PON-1 activity.
In the interpretation of the results, it is relevant that serum PON-I activity was assayed with phenyl acetate as substrate. Arylesterase activity, as measured with this type of assay, is widely used in large-scale studies and has the advantage of an approximately normal distribution, making it suitable for multivariable modelling. 22 Moreover, PON-I activity towards phenyl acetate is less variable between subjects compared to its activity towards paraoxon (overviewed in 18). As expected, 15, 22, 39, 40 PON-1 activity was positively related to HDL cholesterol and apoA-I. Its correlation with non-HDL cholesterol and triglycerides is probably explained by an association of PON-1 with very lowdensity lipoproteins which are able to act as a vector for its cellular secretion. 41 Such relations of PON-1 activity with circulating lipoproteins together with the effect of lownormal thyroid function to increase plasma cholesterol and triglycerides 4, 5, 42 underscore the necessity to adjust for (apo) lipoprotein levels when evaluating the relationship of PON-1 activity with variation in thyroid function in euthyroid subjects. In the present study, we only included euthyroid subjects using strict criteria, that is TSH, free T 4 and free T 3 each being within their respective reference range, as done in other reports. 43, 44 Moreover, we excluded subjects with positive antithyroid peroxidase autoantibodies to avoid possible confounding of latent thyroid autoimmunity on inflammatory and oxidative stress as much as possible. 25 T A B L E 1 Clinical and laboratory characteristics in 2206 subjects according to sex-stratified tertiles of paraoxonase-1 (PON-1) activity Apo, apolipoprotein; BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate, HDL, high-density lipoproteins; MetS, metabolic syndrome; T2DM, type 2 diabetes mellitus; UAE, urinary albumin excretion. b, standardized regression coefficient. Data in mean AE SD or in median (interquartile range). For continuous variables, P-values for linear trend are adjusted for age and sex, except for age which was adjusted for sex only. Data with respect to smoking and alcohol consumption are missing in 10 (0.5%) and 11 (0.5%) of the subjects, respectively. Triglycerides, UAE and TSH are log e transformed. For dichotomous variables, P-values are by multinomial chi-square test. VAN TIENHOVEN-WIND ET AL.
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Inconsistent effects of thyroid function status on PON-1 activity have been reported so far. [24] [25] [26] [27] [28] The inverse relation of PON-1 activity with free T 4 as shown in the current study suggests that low-normal thyroid function could contribute to higher PON-1 activity, although it should be emphasized that this relationship was modest. The mechanisms responsible for this relationship are not yet known. It is unclear whether thyroid hormones are able to affect PON-1 gene expression. Paraoxonase-1 (PON-1) is downregulated by interleukin-1 (IL-1) and tumour necrosis factor-a (TNF-a). 45 Hypothyroidism may increase IL-1 and TNF-a, 46 whereas higher levels of TNF-a are also found in subjects with low-normal thyroid function. 47 In addition, oxidized lipids are recognized to inhibit PON-1 activity. 12, 48, 49 In this context, it is relevant that low-density lipoprotein (LDL) oxidation in vitro is exaggerated in both hypothyroidism and hyperthyroidism. 12, 13 Moreover, increased levels of oxidized LDL have been demonstrated in euthyroid subjects with high normal TSH levels. 14 Taken together, these data 14,45-47 make it unlikely that a higher PON-1 activity in relation to low-normal thyroid function is explained by thyroid hormone-mediated effects on IL-1 and TNF-a or on (systemic) oxidative stress. Given the inverse though modest relation of PON-1 activity with free T 4 , it seems plausible that other mechanisms than effects of PON-1 on oxidative stress defence could contribute to the previously reported enhanced oxidative stress in the context of low-normal thyroid function. 14 It also seems unlikely that changes in PON-1 activity play a major role in an attenuated ability of HDL to protect against LDL oxidation in vitro in subjects with low-normal thyroid function, 8 a read-out of HDL functionality which is closely related to PON-1 activity. 50 In this regard, it is relevant that other factors affecting oxidative stress such as superoxide dismutase 51 and circulating bilirubin levels 43 are also affected by thyroid function. Of note, it has been demonstrated recently that the inverse relationship of bilirubin with free T4 is stronger in more insulin-resistant individuals 43 and that the relationship of PON-1 activity with its activator, apoE, is impaired in subjects with MetS. 40 For this reason, we also set out to determine whether the relationship of PON-1 activity was modified in the context of MetS. We found that the inverse relationship of PON-1 activity with free T 4 was not modified by the presence of MetS nor by its individual components. The regulation of PON-1 is dependent on many genetic and environmental factors. Regarding environmental factors, several animal and human studies have shown that dietary lipids can influence PON-1 activity. [52] [53] [54] Furthermore, it has been reported that physically active subjects have higher PON-1 activity. 55 A limitation of the present study is that detailed information on nutrient intake and data with respect to physical activity were not available. Statins may also increase PON-1 activity, 56 although this has not been unequivocally reported. 57 In the current report, PON-1 activity was not affected by the use of lipidlowering drugs. However, PON-1 activity was inversely associated with the use of glucose-lowering medication in analysis in which we also adjusted for the presence of T2DM. We explain this finding by assuming that the use of glucose-lowering drugs preferentially labels diabetic patients with more severe hyperglycaemia, requiring medical drug treatment. Further, PON-1 activity was elevated in women who used oral contraceptives. Although little information is available on this issue, it seems consistent with F I G U R E 1 Thyroid stimulating hormone (TSH), and free T 4 and free T 3 levels according to sex-stratified tertiles of serum paraoxonase-1 (PON-1) activity. P-values for linear trend (adjusted for age and sex): TSH: P = .036, free T 4 : P = .050 and free T 3 : P = .20. Data are given in means and standard errors. TSH is logarithmically transformed some other data suggesting that PON-1 activity is higher in women taking oral contraceptives and may increase in response to ethinyl oestradiol and cyproterone acetate combination. 58, 59 Several other methodological aspects and limitations of our study need to be considered. We performed a crosssectional study, so that conclusions regarding cause-effect relationships cannot be drawn with certainty. However, we are not aware of any data underscoring a physiological role of PON-1 itself in thyroid hormone regulation. In addition, owing to the observational nature of our study, residual confounding due to unmeasured confounders cannot be entirely ruled out. We performed secondary analyses after exclusion of subjects with a history of CVD and T2DM, and the use of glucose-lowering, lipid-lowering, antihypertensive medication and oral contraceptives. Reassuringly, these analyses showed the same inverse relationship of T A B L E 2 Multiple linear regression models demonstrating the independent association of free T 4 and TSH with paraoxonase-1 (PON-1) PON-1 activity with free T 4 . Of further note, PON-1 activity was assayed in sera that were stored for a prolonged period. However, loss of PON-1 enzymatic activity is minimal if samples stored frozen at À70°C.
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In conclusion, this large population-based cohort study demonstrates for the first time that serum PON-1 activity is inversely associated with free T 4 in euthyroid subjects. It is conceivable that low-normal thyroid function may influence PON-1 regulation.
